Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries ARS Pharmaceuticals, Inc. - Common Stock (NQ: SPRY ) 14.00 -0.45 (-3.11%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 837,720 Open 14.31 Bid (Size) 13.85 (1) Ask (Size) 14.25 (5) Prev. Close 14.45 Today's Range 13.76 - 14.58 52wk Range 3.350 - 16.50 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis September 23, 2024 Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference September 10, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Performance YTD +150.90% +150.90% 1 Month +17.25% +17.25% 3 Month +54.02% +54.02% 6 Month +48.94% +48.94% 1 Year +257.14% +257.14% More News Read More ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.) September 09, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Analyst Ratings For ARS Pharmaceuticals September 09, 2024 Via Benzinga Looking Into ARS Pharmaceuticals's Recent Short Interest August 19, 2024 Via Benzinga ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis September 04, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) August 26, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned August 23, 2024 Via Benzinga ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst August 20, 2024 Via Benzinga Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday August 20, 2024 Via Benzinga Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday August 13, 2024 Via Benzinga FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment August 09, 2024 Via Benzinga Exposures Product Safety ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis August 09, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference August 07, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results August 06, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis) June 28, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire SPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024 May 09, 2024 Via InvestorPlace ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results May 09, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand April 30, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray) April 03, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Top 5 Health Care Stocks That May Plunge In March March 28, 2024 Via Benzinga SPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023 March 21, 2024 Via InvestorPlace Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024 March 15, 2024 Via InvestorPlace ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day March 07, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024 March 06, 2024 From ARS Pharmaceuticals, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
